Prácticas en SPSS. Radioterapia estereotáctica extracraneal (SBRT) en el manejo del cáncer de pulmón de células no pequeñas (CPNCP) estadio precoz y oligometástasis pulmonares

Referencias bibliográficas

• Amin MB, Edge SB, et al. AJCC cancer staging manual. 8ª ed. Springer Cham; 2017.
• Aristu J.J., Ciérvide R., Guridi J., Moreno M., Arbea L., Azcona J.D. et al. Radioterapia estereotáctica. Anales Sis San Navarra [Internet]. 2009 [citado 2022 Oct 22]; 32(Suppl 2): 61-71. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272009000400007&lng=es.
• Bade BC, De la Cruz CS. Cáncer de pulmón 2020: epidemiología, etiología y prevención. Clin Chest Med 2020;41(1):1–24.
• Bezjak A., et al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol 2019;37(15):1316-25.
• Brierly JB, Gosporadowicz MK, Wittekind C, editores. UICCC TNM Classification of Malignant Tumours, 8th edition. Publicado por John Wiley & Sons, 2017.
• Burton L, Speiser. Endobronquial brachytherapy in the treatment of lung cancer, chapter 16. Principles and Practice of Brachytherapy Using Afterloading Systems. Edited By CAF Joslin, A Fynn, EJ Hall. pp 225-239, 2001.
• Chi A, et al. Systemic review of patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: Clinical implications. Radiotherapy and Oncology 94 (2010) 1-11.
• Classification for Lung Cancer. J Thorac Oncol 2016 Jan;11(1):39-51.
• Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. May 28, 2009. U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute.
• De Ruysscher D., Corinne Faivre-Finn C., et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer Radiotherapy and Oncology 2017;124:1-10.
• Detterbeck FC. La octava edición TNM clasificación de estadios para el cáncer de pulmón: ¿Qué significa en la calle principal? J Thorac Cardiovasc Surg. 2018;155(1):356–9.
• Donovan EK, Swaminath A. Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives. Lung Cancer (Auckl). 2018; 9:13-23.
• Fernández Letón P, Baños Capilla C, Bea Gilabert J, Delgado Rodríguez JM, de Blas Piñol R, Martínez Ortega J, Pérez Moreno JM, Simón de Blas R. Recomendaciones de la Sociedad Española de Física Médica (SEFM) sobre implementación y uso clínico de radioterapia estereotáxica extracraneal (SBRT). Rev Fis Med [Internet]. 29 de diciembre de 2017 [citado 23 de octubre de 2022];18(2). Disponible en: https://revistadefisicamedica.es/index.php/rfm/article/view/247
• Goldstraw P, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM
• Guckenberger M, Andratschke N, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 2017;124(1):11-7
• Halperin E.C. Perez and Brady’s Principles and Practice of Radiation Oncology. Lippincott Williams and Wilkins. 7th Ed; 2017.
• Hansen EK, Roach III M. Handbook of Evidence-Based Radiation Oncology. Springer Cham. 3th Ed; 2018.
• Hara R, Itami J, Aruga T, et al. Risk factors for massive hemoptysis after endobronchial brachytherapy in patients with tracheobronchial malignancies. Cancer 2001;92:2623.
• Isla D., de Lozano M., et al. New update to the guidelines on testing predictive biomarkers in non‐small‐cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology 2023;25:1252–67
• Kawamura H, Ebara T, Katoh H, Tamaki T, et al. Long-term results of curative intraluminal high dose rate brachytherapy for endobronchial carcinoma. Radiat Oncol. 2012 Jul 23;7:112.
• Las cifras del cáncer en España, SEOM, Feb 2022. Disponible en: https://seom.org/images/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf
• Macías-Lozano MJ, et al. High dose rate endoluminal brachytherapy in the treatment of endobronchial lesions - experience of a single institution and literature review. Support Care Cancer. 2023 Apr 13;31(5):260.
• Marsiglia H, Baldeyrou P et al. A high-dose rate brachytherapy as sole modality for early stage end bronchial carcinoma. Int J Radiat Oncol Biol Phys 2000;20:665-672.
• Nagata Y, et al. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 2015;93(5):989-96.
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer Version 3.2023 — April 13, 2023 https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [última consulta: Octubre 2023].
• Pierson C, Grinchak T, et al. Response criteria in solid tumors (PERCIST/RECIST) and SUV max in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. Radiat Oncol 2018;13(1):34.
• Revista Americana de Medicina Respiratoria Marzo 2019;19:supl. 1. Disponible en: https://www.ramr.org/articulos/suplemento_concenso_oncologia/suplemento_concenso_oncologia.php#7 [última consulta: Julio 2023].
• Robert D. Timmerman. Stereotactic Body Radiation Therapy in Multiple Organ Sites.,J Clin Oncol 2007;25:947-52.
• SABR UK Consortium. [citado el 23 de octubre de 2022]. Disponible en: https://www.sabr.org.uk/wp-content/uploads/2019/04/SABRconsortium-guidelines-2019-v6.1.0.pdf
• SBRT y Gating — Radioterapia HM [Internet]. Radioterapia HM. [citado el 23 de octubre de 2022]. Disponible en: http://www.radioterapiahm.com/new-page-2
• SEER Cancer Stats Disponible en: https://seer.cancer.gov/statfacts/html/lungb.html [última consulta: Octubre 2023].
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33.
• Stereotactic ablative radiotherapy (SABR/SBRT) [Internet]. Stanfordhealthcare.org. [citado el 23 de octubre de 2022]. Disponible en: https://stanfordhealthcare.org/medical-treatments/s/stereotactic-body-radiation-therapy.html
• Sung H. Global cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49
• Tang H, Wang S, Xiao G, Schiller J, et al. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Ann Oncol 2017;1;28(4):733-40.
• Timmerman RD, et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol 2018;4(9):1263-1266
• Timmerman, R., et al., Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol, 2006; 24(30): 4833-9 Travis W. The 2015 WHO classification of lung tumors. Pathologe. 2014; 35 [Suppl 2]: 188-188.
• Travis WD, Brambilla E, Geisinger KR. Histological grading in lung cancer: one system for all or separate systems for each histological type? Eur Respir J. 2016; 47(3): 720-3.
• Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK. The role of high- dose-rate brachytherapy in the palliation of symptoms in patients with non- small-cell lung cancer: a systematic review. Brachytherapy 2006;5:189–202.
• Van Limbergen, E, Skowronek J., Pötter R. The GEC ESTRO Handbook of Brachytherapy. Part II Clinical Practice Bronchus Cancer chapter 29. Editors Van Limbergen E., Pötter R, Hoskin P., Baltas D., pp 0-23, 2017.
• Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology. 2020;25 Suppl 2(S2):61-71.
• Wang M., Herbst R. S., et al. Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine 2021;27:1345-56.
• Warth A, Muley T, Kossakowski C, Stenzinger A, et al. Prognostic impact and clinicopathological correlations of the cribiform pattern in pulmonary adenocarcinoma. J Thorac Oncol. 2015; 10: 638-644.
• Warth A, Muley T, Kossakowski CA, Goeppert B, et al. Prognostic Impact of Intraalveolar Tumor Spread in Pulmonary Adenocarcinoma. Am J Surg Pathol. 2015; 39(6): 793-801.
• Youroukou A, Gkiozos I, et al. The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review. Clin Transl Oncol. 2017;19(8):945-50.
• Zhao Y, Wang R, Shen X, et al. Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis. Ann Surg Oncol. 2016; 23(6): 2099-2105.